Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
MENLO PARK, Calif., April 05, 2016 -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the 15th Annual Needham Healthcare Conference in New York at 8:40 a.m. Eastern Time on Tuesday, April 12, 2016.
A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website and at http://wsw.com/webcast/needham76/gern. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
